a WORLD LEADER In REGENERATIVE MEDICINE FOR HEART FAILURE
Next Generation Treatment of Heart Failure
Founded by Nobel Laureate Sir Martin Evans, Cardiogeni is pioneering a breakthrough class of cellular therapies designed to reverse heart failure, a condition that touches 1 in 4 people in their lifetime. Our lead candidate and the broader family of engineered therapies aim to repair damaged heart tissue, restore cardiac performance, and deliver renewed quality of life. Welcome to the future of cardiac care.
Dedicated to advancing healthcare, we are inspired to develop a first-in-class pipeline of life-saving medicines. With a mission rooted in innovation and impact, our work is driven by precision, purpose, and a commitment to improving the lives of patients living with heart failure.
Science
Cutting edge science in epigenetic regulated tissue engineering from our Nobel Prize winning founder. Cardiogeni has developed a pipeline of proprietary off-the-shelf cell therapies with a manufacturing cost of goods more typical of a small molecule pharmaceutical product.
About
Innovation meets compassion, as we endeavour to impact the lives of patients living with heart failure. At Cardiogeni, we are dedicated to advancing human health through cutting-edge research, streamlined clinical development and thoughtful dialogue about wellness and vitality.
Investors
World-class science combined with commercial success has led to development of a clinical pipeline of heart failure medicines with less than £20M capital deployment. Cardiogeni is undertaking a market approval trial for its lead medicine to treat heart failure patients undergoing bypass surgery.
Announcements
Cardiogeni is leading a revolution in heart failure treatment with clearly defined short- and medium-term value inflection points built on both clinical and commercial milestones. Follow our news and join our journey as we build the world leader in regenerative heart failure medicine.